PWA
SRPT icon

Principia Wealth Advisory’s Sarepta Therapeutics SRPT Stock Holding History

Principia Wealth Advisory’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90 Hold
5
– – ﹤0.01% 1037
2026
Q1 		$109 Hold
5
– – ﹤0.01% 1006
2025
Q4 		$108 Hold
5
– – ﹤0.01% 970
2025
Q3 		$96 Buy
+5
New +$89 ﹤0.01% 936
2025
Q1 		– Sell
-1
Closed -$122 – 908
2024
Q4 		$122 Buy
+1
New +$123 ﹤0.01% 760

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Principia Wealth Advisory's SRPT Position: Q2 2026 in Review

Principia Wealth Advisory held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 5 shares worth $90. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

Principia Wealth Advisory first reported a position in SRPT in Q4 2024 and has held it in 5 quarters since. The position peaked at $122 in Q4 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Principia Wealth Advisory held 5 shares of Sarepta Therapeutics worth $90 as of Q2 2026.
  • Principia Wealth Advisory left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q2 2026, its #1037 holding.
  • Principia Wealth Advisory first reported a position in Sarepta Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Principia Wealth Advisory's Sarepta Therapeutics position peaked at $122 in Q4 2024.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Principia Wealth Advisory's 13F filing for Q2 2026, filed 26 Aug 2026.